Yang Chi-Shun, Choi Euna, Idrees Muhammad T, Chen Shaoxiong, Wu Howard H
Department of Pathology and Laboratory Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
Cancer Cytopathol. 2017 Jun;125(6):407-415. doi: 10.1002/cncy.21852. Epub 2017 Mar 23.
In recent years, there have been increasing indications for percutaneous renal biopsy. Fine-needle aspiration (FNA), with or without core needle biopsy (CB), has been used increasingly in the management of renal tumors at the study institution.
A computerized search of laboratory records was conducted to retrieve FNA cases of renal masses as well as the correlating CB and/or nephrectomy specimens. The cases spanned a period of 10 years (2006-2015). The diagnoses were classified into 5 categories: malignant, suspicious for malignancy, neoplastic, atypical, and negative/nondiagnostic. Based on the results of the nephrectomy specimens, the diagnostic rate, sensitivity, and diagnostic accuracy were calculated among 3 groups of specimens: FNA only, CB only, and combined FNA and CB.
A total of 247 cases of FNA with 123 correlating CB and 101 follow-up nephrectomy specimens were identified. The diagnostic rate, sensitivity, and diagnostic accuracy were 72%, 78%, and 96%, respectively, for FNA; 87%, 92%, and 94%, respectively, for CB; and 92%, 92%, and 94%, respectively, for the combined FNA and CB group. Renal cell carcinoma and its variants were the most common histologic diagnoses (112 of 174 cases; 64%). Significant diagnostic discrepancy was noted in one case: a malignant melanoma that was misdiagnosed as renal cell carcinoma in both the preoperative FNA specimen and in the CB specimen.
In the current study, both FNA and CB demonstrated excellent diagnostic accuracy (96% and 94%, respectively). The combination of FNA and CB was found to significantly improve the diagnostic rate when compared with either FNA alone (92% vs 72%; P<.05) or CB alone (92% vs 87%). Cancer Cytopathol 2017;125:407-15. © 2017 American Cancer Society.
近年来,经皮肾活检的适应证不断增加。在本研究机构,细针穿刺抽吸活检(FNA),无论有无粗针活检(CB),在肾肿瘤的治疗中使用得越来越多。
通过计算机检索实验室记录,以获取肾肿块的FNA病例以及相关的CB和/或肾切除标本。这些病例跨度为10年(2006 - 2015年)。诊断分为5类:恶性、可疑恶性、肿瘤性、非典型性以及阴性/未诊断。根据肾切除标本的结果,计算3组标本(仅FNA、仅CB以及联合FNA和CB)的诊断率、敏感性和诊断准确性。
共确定了247例FNA病例,其中123例有相关的CB,101例有后续的肾切除标本。FNA的诊断率、敏感性和诊断准确性分别为72%、78%和96%;CB分别为87%、92%和94%;联合FNA和CB组分别为92%、92%和94%。肾细胞癌及其变异型是最常见的组织学诊断(174例中的112例;64%)。在1例中发现了显著的诊断差异:1例恶性黑色素瘤在术前FNA标本和CB标本中均被误诊为肾细胞癌。
在本研究中,FNA和CB均显示出优异的诊断准确性(分别为96%和94%)。与单独使用FNA(92%对72%;P<0.05)或单独使用CB(92%对87%)相比,联合使用FNA和CB可显著提高诊断率。《癌症细胞病理学》2017年;125:407 - 15。©2017美国癌症协会。